Angelini Pharma to Acquire Catalyst Pharmaceuticals
May 7, 2026 · Following completion of the acquisition, Angelini Pharma intends to integrate Catalyst’s portfolio and exceptional commercial infrastructure with its own expertise and products in Brain …
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion …
May 7, 2026 · The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third quarter of 2026.
Press releases - Angelini Pharma
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion …
May 7, 2026 · Angelini will pay $31.50 for each of Nasdaq-listed Catalyst’s outstanding shares for a total consideration of about 3.5 billion euros, equivalent to $4.1 billion, the companies said...
Italian pharma Angelini scoops up Catalyst in $4.1B deal
May 7, 2026 · Italy’s Angelini Pharma has acquired Florida-based rare disease specialist Catalyst and its potential blockbuster Firdapse for $4.1 billion.
Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion
May 8, 2026 · Angelini Pharma has agreed to acquire Coral Gables, Florida-based Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the deal at about $4.1 billion, the...
Angelini buys rare-disease focused Catalyst for $4.1B - STAT
May 7, 2026 · The Italian company Angelini Pharma said Thursday it would buy the rare-disease focused Catalyst Pharmaceuticals for roughly $4.1 billion in cash.
Angelini Pharma to acquire Catalyst Pharmaceuticals, entering the …
May 8, 2026 · This acquisition, announced on May 7 2026, marks a pivotal moment in the Angelini Group’s history, as it strengthens Angelini Pharma's presence in the U.S. market, reinforcing its long …
Kirkland Advises Catalyst Pharmaceuticals on $4.1 Billion Sale to Angelini
May 7, 2026 · Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for $31.50 per share in cash, for a total equity value of approximately $4.1 billion (equivalent to 3.5 billion euros.)
Angelini Pharma Enters $ 4.1 Billion Agreement to Acquire Catalyst ...
May 7, 2026 · Angelini Pharma agreed to acquire Catalyst Pharmaceuticals in a deal valued upwards of $4.1 billion in cash. The acquisition provides the Italian pharmaceutical company a commercial …
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion …
May 7, 2026 · The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third quarter of 2026.